Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT01949662
PHASE2

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

Sponsor: M.D. Anderson Cancer Center

View on ClinicalTrials.gov

Summary

This randomized phase II trial studies how well haloperidol with or without lorazepam works in reducing confusion, disorientation, and inability to think or remember clearly (delirium) in patients with cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Palliative therapy with haloperidol and lorazepam may reduce symptoms of delirium and help patients with advanced cancer live more comfortably. It is not yet known whether lorazepam may be an effective treatment for delirium when given with haloperidol.

Official title: A Preliminary Double-Blind Randomized Controlled Trial of Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer Admitted to a Palliative Care Unit

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

93

Start Date

2014-01

Completion Date

2028-01-01

Last Updated

2026-02-13

Healthy Volunteers

No

Interventions

DRUG

Lorazepam

3 mg by vein one time only.

DRUG

Placebo

Placebo consisting of preservative free 0.9% normal saline given one time by vein.

DRUG

Haloperidol decanoate

8 mg/day by vein.

BEHAVIORAL

Questionnaires

Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete.

Locations (1)

University of Texas MD Anderson Cancer Center

Houston, Texas, United States